CD274 and non-small cell lung carcinoma: The phase III CheckMate 227 trial, enrolling patients with stage IV or recurrent NSCLC treated with the combination of nivolumab and the anti-Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) ipilimumab (vs. chemotherapy or vs. nivolumab), showed a benefit in progression free survival (PFS) in the group treated with ICB (vs. chemotherapy) having a high TMB (≥10 mutations per megabase), irrespective of the PD-L1 expression level (15).